Zhejiang Ausun Pharmaceutical Co., Ltd.
Summary
Revenue :
000,000 M USD
Finance :
000,000 M USD
Earning Cap :
000,000 M USD
Invest :
000,000 M USD
R & D :
0000 People
Growth :
00% AGR
DIGDAL CAP
Overview
| General Introduction | Zhejiang Aoxiang Pharmaceutical Co., Ltd. was established in April 2010 and was listed on the Shanghai Stock Exchange on May 9, 2017 under the stock code 603229. The company is located in the Chemical Raw Material Drug Base Linhai Park of Toumen Port Economic Development Zone in Zhejiang Province. It is the first pharmaceutical enterprise in Taizhou to have an academician workstation and also a high-tech enterprise. At present, the company has established excellent platforms such as Zhejiang Provincial Research Institute, Provincial Enterprise Technology Center, Provincial Academician Expert Workstation, and Provincial Postdoctoral Workstation. There are nearly 800 employees and a research, development, and analysis team consisting of over 200 people, including doctoral and master's degrees. The company is mainly engaged in the research and development, production, and sales of pharmaceutical preparations, characteristic raw materials, and key pharmaceutical intermediates, as well as providing customized processing and research and development services for customers; The products are mainly exported to countries and regions such as Europe, the United States, Japan, and South Korea. From January to June 2020, the company's operating revenue increased by 62.38% year-on-year, and its net profit increased by 69.46% year-on-year. The company's products are mainly divided into eight categories: liver disease, respiratory system, cardiovascular and cerebrovascular, high-end fluoride products, prostaglandins, antibiotics, gout, and anti-tumor. The developed products have multiple chiral structures, high research and development difficulties, high technical barriers, and unique production processes. The company attaches great importance to technological innovation and research and development. In the past three years, research and development investment has accounted for more than 12% of operating revenue (with a proportion of 15.51% in 2019). The company focuses on the health industry, always adhering to the core concept of "quality+innovation", with the corporate purpose of "serving health and jointly creating the future". In accordance with the requirements of China's pharmaceutical industry's "14th Five Year Plan" industry plan and the national innovation development strategy, and guided by the development concept of "talent and win-win", the company aims to create an internationally first-class research and development innovation system with new drug creation capabilities and generic drug technology, while continuously expanding the coverage of its sales network, Actively exploring high-end standardized markets such as the United States, Japan, and Europe, striving to become a globally competitive specialty pharmaceutical enterprise in the future. |
| Headquarter | Taizhou |
| Establish Date | 4/22/2010 |
| Listed Code | 603229.SH |
| Listed Date | 5/9/2017 |
| Chairman | Zheng Zhiguo. |
| CEO | Zheng Zhiguo. |
| Website | www.ausunpharm.com |
Buy Premium Now
$15/month billed now
View the full stack of insights immediately
Or 7 Days Free Charge for Trial
See feature available in the Trial and Premium
See our Solution and Servicetrial.solutionservice.trial
See our Uniquness and Value deliveringtrial.solutionservice.trial
